Skip To The Main Content
2021 Endotoxins Workshop

2021 PDA Endotoxins Workshop

Practical Insights into the Evolution of Endotoxin Testing

Oct 07, 2021
Eastern Standard Time | Online
  • Virtual
  • Online
Program Highlights
Now fully virtual! This is the one endotoxins workshop you don’t want to miss. Best part of all is that you can attend from the comfort of your home or office wherever you are!


On behalf of the Program Planning Committee and PDA, we would like to invite you to the 2021 PDA Endotoxins Workshop on 07 October 2021. The agenda will focus on the theme of “Practical Insights into the Evolution of Endotoxin Testing”.

Endotoxin, a cell wall component of gram negative bacteria, can cause varying levels of immune responses when introduced to the blood system. As a result, the onus is on the manufacturers of all parenteral drugs to control possible endotoxin contamination throughout the manufacturing process. As pharmaceutical manufacturing processes continue to become more streamlined and new therapy delivery continues to evolve, endotoxin control is evolving as well.

The 2021 PDA Endotoxins Workshop will provide scientific understanding and real-world practices for endotoxin testing in bio/pharmaceutical production processes.
Major topics to be covered will include:

  • Recombinant Reagent
  • Automation
  • Data Integrity
  • The Pyrogenic Dose, Specifications and Co-infusions
  • Regulatory Compendia

We look forward to seeing you at the 2021 PDA Endotoxins Workshop online!


  • Thursday, 07 October

    08:45 – 10:30 | Plenary 1: Recombinant Reagent
    Moderator: Anders Thorn, M.Sc. Pharm, Principal Scientist, Microbial Competence Centre, Novo Nordisk A/S

    Recombinant reagents for endotoxin detection has been available for many years as an alternate to LAL-based testing and it has been an official method for test for endotoxin in the European Pharmacopeia since January 2021 although comparison of the performance of recombinant reagents and LAL is still subject to discussion.
    This session will discuss strategies for validation and for implementation of the recombinant reagents for endotoxins testing. Furthermore, studies that evaluates the use of recombinant technology for the detection of environmental endotoxin will be summarized.

    Welcome from the Program Planning Committee Co-Chair

    rFC Implementation Strategy for Endotoxin Testing at Sanofi Pasteur
    Thierry Bonnevay, Sanofi

    Method Validation Strategy for Endotoxin Testing of Water Samples with Recombinant Factor C
    Evelyn Der, Genentech

    Results and Benefits of using a Novel Recombinant Factor C Assay for Human Tissue Endotoxin Testing
    Victoria Rensink, XTANT Medical

    Review of Alternatives to Horseshoe Crab Lysates for Endotoxin Testing
    Ned Mozier, Pfizer

    Q&A Panel Discussion


    10:45 – 12:15 | Plenary 2: Automation/Data Integrity
    Moderator: Jessica Hankins, Associate Scientific Director, Microbiology Center of Excellence Analytical Strategy and Operations, Bristol Myers Squibb

    Automation technologies for bacterial endotoxin testing can improve efficiency and decrease assay variability. This session will focus on providing end-user perspectives when implementing automation technologies in coordination with bacterial endotoxin testing. Vendor representatives will be present for the Question and Answer session to provide additional insights on the various technologies discussed during the session.

    Lessons Learned and Benefits Gained from the Global Implementation of an Automated Endotoxin Testing Solution
    Phil Duncanson, PhD, Chief Microbiologist, Global Quality, AstraZeneca

    End-User Perspective
    Mike Knight, Associate Director, QC Microbiology, Genentech

    Holy Crab! A Simple, Automated Sample-to-Answer Recombinant Factor C Assay for Bacterial Endotoxins: A Deeper Dive
    Benjamin Claywell, Eli Lilly and Company

    Q&A Panel Discussion
    • Josiah Hosie, Lonza
    • Wilhelm Johnsson, Charles River
    • Kevin Miller, Hamilton
    • Kevin Williams, bioMerieux


    12:30 – 14:00 | Plenary 3: Current Topics in Endotoxin: The Pyrogenic Dose, Specifications and Co-infusions
    Moderator: Jay Bolden, Associate Quality Advisor-Biologist, Global Quality Laboratories, Eli Lilly and Company

    This session will link the past to the present, and connect theory to patient safety in a clinical setting. The audience will hear the history and development of the threshold pyrogenic dose as it relates to specification setting, and learn about endotoxins and endotoxemia in the area of global patient safety.

    TPD, Rabbits/humans, 2X Safety Factor, Real Endotoxin vs. Purified, Impact of FDA-Requested 2X cut
    Karen McCullough, Principal Consultant, MMI Associates, LLC

    Clinical Relevance of Specification/Co-infusion Impacts to Patient Safety
    Doug Roepke, MD, Medical Fellow, GPS Medical - Product Safety Assessment, Eli Lilly & Company

    Q&A Panel Discussion


    14:15 – 15:45 | Plenary 4: Regulatory Compendia
    Moderator: Ingo Spreitzer, PhD, Deputy Head, Microbiological Safety, Paul-Ehrlich-Institut (PEI)

    During the last 20 years new methods in the field of Endotoxin/Pyrogen testing have been developed to marketability. The European Pharmacopeia has incorporated these methods in General Chapters, the pharmaceutical industry is asking for global adjustment (harmonization). Hear perspectives from global pharmacopeias and the FDA on the current position towards rFC (MAT), next steps and harmonization.

    EDQM – European Pharmacopoeia Approach to Testing for Pyrogenicity
    Emmanuelle Charton, PhD, Head of Division B, European Pharmacopoeia Department EDQM

    Japanese Pharmacopoeia on rFC
    Yutaka Kikuchi, PhD, Expert Committee, Professor, Department of Nutrition, Faculty of Healthcare Sciences Chiba Prefectural University of Health Sciences, Japanese Pharmacopeia

    FDA Vision on rFC and MAT
    Reyes Candau-Chacon, PhD, Review Microbiologist, Division of Biotechnology Assessment, CDER, U.S. FDA

    Q&A Panel Discussion

Highlighted Speakers

Reyes Candau-Chacon
Reyes Candau-Chacon
Emmanuelle Charton
Emmanuelle Charton
Phil Duncanson
Phil Duncanson
Karen Z. McCullough
Karen Z. McCullough
MMI Associates
Victoria Rensink
Victoria Rensink
Xtant Medical
Kevin L. Williams
Kevin L. Williams

Learning Objectives

Upon completion of this workshop, you will be able to:
  1. Understand complex interaction of endotoxins with immune system
  2. Identify the best test method for endotoxin analysis for your company’s purpose
  3. Select appropriate endotoxin specifications for your company’s products
  4. Describe best practices for your company’s new or existing laboratories

Registration Fees

Register Now
Registration Type Regular Registration
Price after 30 September 2021
Member $837 $1,076
Non-member $1,033 $1,328
Govern./Health Authority/Academic Member $392 $504
Govern./Health Authority/Academic Non-member $448 $576
Student Member $157 $202
Student Non-member $174 $223
Early Career Professional
$419 $538

Got a Question? We have answers

Contact Us
Become a Sponsor

Interested in becoming a sponsor? Learn about opportunities and benefits.

Request Information


Become an Exhibitor

Interested in becoming an exhibitor? Learn about opportunities and benefits.

Request Information

Attendee List Email Scam

Unfortunately, emails are circulating that offer to sell attendee lists for many of PDA’s conferences and events. These emails are sent by scammers.

Note: PDA does not sell its exhibitor or attendee lists, and no third-party is authorized to distribute or sell any lists related to our events. Statements claiming to offer our attendee lists are fraudulent. If you receive emails that propose to sell PDA conference attendee lists, do not engage with the sender and delete the message immediately.

Media Partners

Related Events


Program Inquiries
Exhibition Inquiries
Course Inquiries
Registration Customer Care

Tel: +1 (301) 656-5900 ext. 115
[email protected]

PDA Members Save Substantially